Cytoguide Overview

  • Founded
  • 2007
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A

Cytoguide General Information

Description

Developer of combined drugs that target receptors on cells in pathological tissues. The company offers drugs that are aimed to improve the treatment of onocyte and macrophage-related diseases including autoimmune disease, leukemia and other infectious diseases.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Acquirer
Primary Office
  • INCUBA Science Park
  • Gustav Wieds Vej 10
  • 8200 Aarhus
  • Denmark
+45 86 00 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Cytoguide Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 01-Oct-2013 00.000 Completed Generating Revenue
4. Early Stage VC 08-Dec-2010 00.000 Completed Startup
3. Early Stage VC 02-Jun-2009 00.000 Completed Startup
2. Early Stage VC 28-Nov-2008 $2.39M $2.68M Completed Startup
1. Seed Round 01-Nov-2007 $287K $287K Completed Startup
To view Cytoguide’s complete valuation and funding history, request access »

Cytoguide Executive Team (2)

Name Title Board Seat Contact Info
Søren Moestrup Ph.D Chief Scientific Officer & Co-Founder
You’re viewing 1 of 2 executive team members. Get the full list »

Cytoguide Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Capnova Venture Capital Minority 000 0000 000000 0
Karolinska Development Venture Capital Minority 000 0000 000000 0
Lund University Bioscience Venture Capital Minority 000 0000 000000 0
Novo Holdings Venture Capital Minority 000 0000 000000 0
To view Cytoguide’s complete investors history, request access »